Novel antiplatelet drugs in clinical development

Thromb Haemost. 2013 Nov;110(5):868-75. doi: 10.1160/TH13-02-0084. Epub 2013 Oct 10.


The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold promise to improve this benefit-risk ratio.

Publication types

  • Review

MeSH terms

  • Animals
  • Cerebrovascular Disorders / drug therapy*
  • Clinical Trials as Topic
  • Drug Discovery
  • Humans
  • Platelet Aggregation Inhibitors / pharmacology
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Purinergic P2Y Receptor Antagonists / therapeutic use*
  • Receptor, PAR-1 / antagonists & inhibitors
  • Risk Assessment


  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Purinergic P2Y Receptor Antagonists
  • Receptor, PAR-1